Merck and Moderna report success in late-stage trial of personalized mRNA cancer vaccine

Merck and Moderna announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a randomized late-stage trial, marking the first demonstration that such an approach can be effective.

The study compared the vaccine plus standard therapy against standard therapy alone and showed a statistically significant improvement in outcomes, suggesting mRNA technology could become a new pillar in oncology.

The same newsletter also highlighted scrutiny of Huidagene after a patient death raised concerns about its disclosures, and noted that a new nominee is expected to lead the FDA as commissioner.